1. Home
  2. IZEA vs ANVS Comparison

IZEA vs ANVS Comparison

Compare IZEA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IZEA Worldwide Inc.

IZEA

IZEA Worldwide Inc.

HOLD

Current Price

$3.60

Market Cap

62.9M

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.96

Market Cap

69.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IZEA
ANVS
Founded
2006
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
62.9M
69.1M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
IZEA
ANVS
Price
$3.60
$1.96
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
48.9K
979.1K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
39.39
EPS
N/A
N/A
Revenue
$20,099,695.00
N/A
Revenue This Year
$20.81
N/A
Revenue Next Year
$14.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$1.54
52 Week High
$5.86
$5.50

Technical Indicators

Market Signals
Indicator
IZEA
ANVS
Relative Strength Index (RSI) 48.49 55.14
Support Level $3.58 $1.92
Resistance Level $3.93 $2.07
Average True Range (ATR) 0.16 0.10
MACD 0.02 0.03
Stochastic Oscillator 65.91 76.00

Price Performance

Historical Comparison
IZEA
ANVS

About IZEA IZEA Worldwide Inc.

IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: